Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma

NCT05431764 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Camrelizumab, gemcitabin, cisplatin
RADIATION: Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy

Sponsor

Sun Yat-sen University